Overall rank by patents
#15,310
of 50,000 tracked assignees
USPTO PatentsView assignee record - 19 granted patents across 14 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).
The verdict
According to USPTO PatentsView, Genemind ranks #15,310 of 50,000 tracked US assignees by granted-patent volume, with 19 patents across 14 technology areas.
USPTO PatentsView assignee plate
Corpus R15310 · Foreign Corporation #15,310 · 19 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Gaodi Digital (qingdao) Co., Ltd. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Genemind Biosciences · this assignee
47 score
3D Lighting Innovati… · lowest
7 score
What this shows Genemind Biosciences Company Limited stamps GRANTS-MICRO, MID-PACK, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-RICH, TYPE-FRNCORP, VEL-SURGE, BOOK-FULL. Volume places it #15,310 of 50,000; Innovation Score 46.9/100 sits in the top 20% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Gaodi Digital (qingdao) Co., Ltd. (±0 grants).
Genemind Biosciences Company Limited has been granted 19 US utility patents between 2019 and 2025, placing Genemind Biosciences Company Limited at #15,310 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 14 distinct Cooperative Patent Classification (CPC) subclasses, averaging 16.6 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a Foreign Corporation, Genemind Biosciences Company Limited is one of the more focused assignees in the PatentsView dataset. By volume, Genemind sits between GSG Holdings, Inc. (19 patents, rank #15,310) and Global Circuit Innovations Incorporated (19 patents, rank #15,318) - the closest US assignees by grant volume. The composite Innovation Score of 46.9/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 12 grants, compared with 3 in the 2015–2019 window, a +300% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Genemind Biosciences Company Limited's 16.6 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 14 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
GSG Holdings, Inc.
19 patents
GUANGZHOU SHENGWEI ELECTRIC MANUFACTURING CO., LTD.
19 patents
Gaodi Digital (Qingdao) Co., Ltd.
19 patents
Gas Technologies LLC
19 patents
Genesis Medical Devices LLC
19 patents
Georgia-Pacific LLC
19 patents
Giner, Inc.
19 patents
Global Circuit Innovations Incorporated
19 patents
GeneMind Biosciences Company Limited
19 patents
What this shows Genemind holds 19 patents at rank #15,314, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #15,314 in granted patent volume.
Other assignees with the most granted patents in Genemind's primary technology class.
Genemind's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
47 Top 20% higher than 80% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 3 | 15.8% |
| 2021 | 2 | 10.5% |
| 2022 | 5 | 26.3% |
| 2023 | 2 | 10.5% |
| 2024 | 3 | 15.8% |
| 2025partial year | 4 | 21.1% |
Top 14 of 14 technology areas
Overall rank by patents
#15,310
of 50,000 tracked assignees
46.9 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.